IVF Risks and Practical Considerations: What Patients Should Know
Key Takeaways
IVF is generally safe, but it is not risk-free. The main medical concerns are ovarian hyperstimulation syndrome, egg retrieval complications, and multiple pregnancy when more than one embryo is transferred. Individualized protocols, careful monitoring, single embryo transfer, and clear recovery instructions minimize these risks without eliminating them entirely.
Key evidence: ASRM guideline on preventing moderate and severe OHSS (2023) ASRM guidance on limits to the number of embryos transferred (2021) Levi-Setti et al. complications cohort in 23,827 oocyte retrievals (2018)
Reading a list of IVF complications all at once can feel overwhelming. Conversely, hearing simply that “the treatment is safe” is unhelpful if your practical questions remain unanswered.
The clinical reality sits in between: the vast majority of IVF cycles proceed without severe adverse events, but every phase carries distinct physiological, emotional, and logistical factors that deserve transparent discussion before you begin.
Informed consent is not about memorizing rare possibilities. It is about understanding what applies to your individual health profile, how your clinical team acts to prevent complications, and which warning signs warrant immediate contact.
IVF Risks at a Glance
Short answer: The primary medical risks in IVF stem from ovarian response to stimulation medications, the egg retrieval procedure, and the number of embryos transferred. Longer-term questions about cancer, menopause, and ovarian reserve are covered below. Your personal risk profile depends on your age, ovarian reserve, underlying diagnosis such as PCOS, and protocol selection.
| Risk Area | When Risk Is Higher | Primary Prevention Strategy |
|---|---|---|
| Ovarian Hyperstimulation Syndrome (OHSS) | High antral follicle count, elevated AMH, PCOS, young age | Antagonist protocol, individualized gonadotropin dosing, GnRH agonist trigger, freeze-all strategy |
| Egg Retrieval Complications (bleeding, infection) | Pelvic adhesions, severe endometriosis, prior pelvic surgery | Ultrasound guidance, sterile technique, prophylactic assessment, post-procedure observation |
| Anesthesia or Sedation Side Effects | Respiratory or cardiovascular history, medication sensitivities | Pre-operative anesthetic assessment, monitored sedation, strict fasting adherence |
| Multiple Pregnancy (twins, triplets) | Transferring more than one embryo | Elective single embryo transfer (eSET) when prognosis allows |
| Long-term cancer, menopause, or ovarian reserve | Not clearly established; ovarian and thyroid cancer may be more common after fertility treatment, but endometriosis and not having had a child confound the studies | No specific preventive step; current evidence does not show earlier menopause, direct data on reserve are limited, and there is no strong evidence of higher breast cancer risk |
This summary is not a substitute for an individualized consultation. However, it frames the decisions that genuinely influence cycle safety.
What Is Ovarian Hyperstimulation Syndrome?
Short answer: Ovarian hyperstimulation syndrome (OHSS) is an exaggerated response to fertility drugs, causing ovaries to swell and fluid to leak into the abdominal and pelvic cavities. In severe cases, it can affect breathing, blood volume, and kidney function.
The ASRM 2023 OHSS prevention guideline classifies moderate and severe OHSS as uncommon but clinically serious complications of ovarian stimulation. Women with high baseline anti-Müllerian hormone (AMH) levels, polycystic ovary syndrome (PCOS), or a large cohort of growing follicles face the highest baseline vulnerability.
Mild symptoms—such as mild bloating, abdominal fullness, and slight fatigue—are common as ovaries enlarge. However, rapid weight gain, progressive abdominal distension, intractable nausea, decreased urine output, or shortness of breath signal escalating severity that requires prompt medical evaluation.
Modern clinical practice has substantially reduced the incidence of severe OHSS. When high response is anticipated, the ASRM guideline recommends using a GnRH antagonist protocol paired with a GnRH agonist trigger instead of hCG, alongside a planned freeze-all strategy. Deferring the embryo transfer avoids the secondary hCG surge of early pregnancy, which drives late-onset OHSS. The ESHRE ovarian stimulation guideline (2025 update) recommends freeze-all to minimize the risk of late-onset OHSS. It does not remove every OHSS risk, because symptoms can still appear in the days after egg collection, so follow-up continues. Later pregnancy chances are preserved through a frozen embryo transfer.
What Are the Risks of Egg Retrieval?
Short answer: Egg retrieval is a brief outpatient procedure performed under ultrasound guidance. Because a fine needle traverses the vaginal wall into each ovary, bleeding, localized infection, and adjacent pelvic discomfort remain recognized, though uncommon, risks.
A comprehensive review of transvaginal oocyte retrieval complications identifies pelvic bleeding, intra-abdominal infection, and accidental needle trauma as the main mechanical risks.
In a large clinical series evaluating 23,827 oocyte retrievals (Levi-Setti et al., 2018), the overall complication rate was 0.4%, with hospital admission required in only 0.29% of cases. While these figures reflect high-volume center outcomes and cannot promise an identical outcome for every patient, they put retrieval safety into clear perspective: major complications are rare, but never zero.
Mild pelvic cramping, slight spotting, and fatigue are standard post-procedure sensations. In contrast, sharp or worsening pelvic pain, heavy vaginal bleeding, persistent dizziness, or fever require direct clinical assessment. Our detailed overview of egg retrieval outlines what to expect on procedure day.
Why Is Multiple Pregnancy a Major Avoidable Risk?
Short answer: Carrying twins or triplets substantially increases the risk of preterm birth, low birth weight, gestational diabetes, pre-eclampsia, and neonatal intensive care admission compared to a singleton pregnancy.
The ASRM committee opinion on embryo transfer limits emphasizes that the true goal of assisted reproduction is the healthy birth of a single child. Even uncomplicated twin pregnancies carry higher maternal and perinatal morbidity than singleton gestations.
Transferring multiple embryos at once slightly increases the chance of pregnancy in that specific attempt, but dramatically increases twin rates. By contrast, performing sequential elective single embryo transfers across separate cycles yields equivalent cumulative live-birth rates while keeping maternal-fetal risk at the lowest possible baseline.
For an in-depth review of twin risks and transfer decisions, explore our guide to twin pregnancies in IVF.
Are Later Pregnancy Risks Due to IVF Alone?
Short answer: Higher rates of certain obstetric conditions observed in fertility patients often reflect underlying parental factors—such as maternal age, endometriosis, vascular health, or multiple pregnancy—rather than the laboratory procedure itself.
Epidemiological studies indicate slight increases in placenta previa, gestational hypertension, and cesarean delivery among pregnancies conceived via ART. However, disentangling the impact of IVF technology from the underlying causes of infertility is complex.
Attributing every downstream pregnancy development solely to IVF overlooks the critical role of pre-existing health conditions and maternal age.
Does IVF increase cancer risk or use up ovarian reserve?
Short answer: Stimulation mostly matures follicles that would be lost anyway, and current evidence does not show that IVF brings menopause forward. There is no strong evidence that it increases breast cancer. For ovarian and thyroid cancer the picture is less clear.
Stimulation mainly recruits follicles that began growing that month and would mostly be lost in a natural cycle anyway. Direct long-term data on ovarian reserve are limited. In a Dutch cohort of IVF-treated women, more IVF cycles were not linked to earlier menopause, although follow-up was limited (de Boer et al., 2005).
Some studies have reported small increases in ovarian cancer, especially borderline ovarian tumors. The ASRM 2024 guideline advises telling patients that fertility treatment may be linked to a higher risk of ovarian and thyroid cancer. It is hard to tell whether that comes from the treatment or from underlying factors such as endometriosis and not having had a child.
Dr. Aksoy’s Approach to Risk Management
In our clinical practice, patient anxieties often center around exceedingly rare complications, while the two most substantial risks—severe OHSS and twin gestations—receive less attention.
Our protocol design directly addresses both: we utilize GnRH antagonist protocols and agonist triggers with a freeze-all strategy whenever high ovarian response is identified. Freeze-all reduces the risk of severe OHSS substantially, but it does not bring it to zero, so we keep following symptoms after egg collection. We also advocate elective single embryo transfer (eSET) in all favorable prognostic groups, protecting mothers and infants from the preventable morbidities of multiple gestations.
How Clinical Teams Minimize Treatment Risks
Short answer: Safety begins well before the first injection through thorough baseline diagnostic testing, tailored medication dosing, ultrasound monitoring, and adaptable cycle plans.
Key measures in a comprehensive safety strategy include:
- Tailoring gonadotropin starting doses according to age, AMH, antral follicle count, and body mass index.
- Performing serial ultrasound scans and hormonal assays to track follicle growth and prevent over-response.
- Utilizing GnRH antagonist protocols and agonist triggers when high ovarian response is identified.
- Deferring embryo transfer and vitrifying embryos when hormonal or physical markers suggest elevated OHSS risk.
- Reviewing anesthetic history, medical allergies, and fasting guidelines prior to oocyte retrieval.
- Prioritizing single embryo transfer in favorable prognostic groups.
- Providing written post-procedure recovery instructions and direct clinical emergency contacts.
Adapting a protocol mid-cycle is not a sign of failure; it reflects proactive clinical judgment aimed at maintaining patient safety. The complete step-by-step IVF process explains how each phase is monitored.
The Emotional, Practical, and Financial Burden
Short answer: Treatment demands extend beyond medication schedules. Waiting periods, scheduling adjustments, travel commitments, and financial investments form a vital part of informed planning.
The emotional trajectory of an IVF cycle often brings distinct stress points: the interval between monitoring ultrasounds, the two-week wait after embryo transfer, and the disappointment of an unsuccessful attempt. An unsuccessful cycle does not imply that an error occurred; embryo chromosomal composition, endometrial receptivity, and biological variation all influence outcomes.
For international patients, travel logistics and clinic visits should be organized smoothly so that medical monitoring remains unhurried. Our guide to IVF in Turkey for international patients describes how appointments and care are structured for patients visiting from abroad.
Urgent Warning Signs: When to Seek Medical Attention
Short answer: Severe or progressive pelvic pain, heavy bleeding, high fever, intractable vomiting, rapid abdominal swelling, or fainting after an IVF procedure require immediate medical evaluation.
Contact your clinical team or emergency medical services immediately if you experience:
- Severe, sharp, or worsening abdominal or pelvic pain that does not respond to standard mild analgesics.
- Heavy vaginal bleeding (soaking more than one menstrual pad per hour).
- High fever (temperature above 38°C / 100.4°F) or persistent chills.
- Rapid abdominal swelling or sudden, unexpected weight gain (more than 1 kg / 2.2 lbs in 24 hours).
- Inability to keep fluids down due to persistent nausea and vomiting.
- Marked reduction in urination or very dark, concentrated urine.
- Shortness of breath, chest pain, or severe dizziness/fainting.
- Sudden, asymmetric swelling or pain in one calf or leg.
Do not wait for scheduled follow-ups if red-flag symptoms arise. Prompt clinical assessment gives complications the best chance of being identified and treated early.
Questions to Ask Your Doctor Before Starting
Short answer: Asking specific questions about your individual risk factors and preventive protocols helps align expectations and build confidence.
- What is my individual risk of developing OHSS based on my AMH and follicle count?
- Which stimulation protocol and trigger medication do you plan to use, and why?
- Under what clinical conditions would you recommend a freeze-all cycle over a fresh transfer?
- What type of anesthesia or sedation will be used during my egg retrieval?
- How many embryos do you recommend transferring, and what are the twin risks in my case?
- Who do I contact directly outside normal clinic hours if I experience warning signs?
- How do my age and diagnosis influence our projected IVF success rates?
Related Reading
- Ovarian Stimulation in IVF: How Protocols and Dosing Are Selected
- Egg Retrieval Pain Control: Sedation and Anesthesia Choices
- Twin Pregnancy After IVF: Why Single Embryo Transfer Is Safer
- Fresh vs. Frozen Embryo Transfer: Clinical Indications and Safety
Frequently Asked Questions for Dr. Aksoy
Does IVF increase cancer risk, cause early menopause, or use up ovarian reserve?
One of the worries I hear most often is that IVF medicines will use up a woman’s eggs too soon. In treatment we are trying to mature more of the follicles that have already started to grow that month, most of which would be lost in a natural cycle. Current evidence does not show that IVF rapidly depletes ovarian reserve or brings menopause forward.
Research on cancer is generally reassuring. There is no strong evidence that IVF increases breast cancer. Some studies have reported small increases in ovarian cancer, and especially in borderline ovarian tumors, but we do not know for certain whether that comes from the treatment or from underlying factors such as endometriosis and not having had a child (ASRM, 2024).
I do not tell patients that IVF has no risks. I do explain that the fears that it uses up the eggs, causes early menopause, or directly causes cancer are not supported by the evidence we have.
Is egg retrieval dangerous? What are the real risks?
Egg collection is usually a short procedure, and most patients can go home the same day. It is still not accurate to call it risk-free: we reach the ovaries with a needle.
The complications I watch for are internal bleeding, infection, and, very rarely, injury to the bowel, bladder or a blood vessel. We also assess the risks of sedation or anesthesia before the procedure. I keep in mind ovarian hyperstimulation syndrome (OHSS) from stimulation and the risk that an enlarged ovary could twist.
It is not true that egg collection necessarily damages the ovaries, causes infertility, or uses up the reserve. What matters to me is to describe the real complications without playing them down, and not to turn uncommon risks into an inevitable danger in the patient’s mind.
If there is a risk of OHSS, why freeze the embryos? Does freeze-all stop pregnancy in the same cycle?
When the risk of OHSS rises, my priority is the patient’s safety. This condition can become more severe and last longer if a pregnancy occurs, because hCG, the hormone that rises in early pregnancy, can worsen OHSS.
If I see that risk, I may change the medicine used to mature the eggs and prefer to freeze all the embryos we obtain. In this freeze-all approach we do not do a fresh embryo transfer in the same cycle. So a pregnancy does not start from a transfer that month. That does not mean the chance of pregnancy has been lost. We can transfer the embryos later, once the ovaries have settled (ASRM OHSS prevention guideline, 2023).
This approach reduces the risk of OHSS substantially, but it does not bring it to zero. I therefore keep following the patient’s symptoms after egg collection.
I explain this to patients as postponing pregnancy to a safer time, not as a failure or as cancelling treatment. Waiting a few weeks is sometimes a better decision than taking an unnecessary health risk.
FAQ: more questions about IVF risks
Is IVF considered a safe procedure?
Yes. IVF is widely performed and generally safe when conducted under standardized clinical protocols. However, it remains a medical treatment with specific manageable risks, including OHSS, minor retrieval complications, and emotional strain.
Who has the highest risk of developing OHSS?
Younger women, individuals with high AMH levels, patients with PCOS, and those with more than 15–20 growing follicles during stimulation carry the highest susceptibility. Tailored protocols and agonist triggers significantly mitigate this risk.
How common are severe complications during egg retrieval?
Severe complications are rare. In a large single-center series of 23,827 retrievals published by Levi-Setti et al. (2018), total complications occurred in 0.4% of cases, and hospital admissions were required in 0.29%.
Does a freeze-all cycle eliminate all OHSS risk?
Freezing all embryos and using a GnRH agonist trigger reduces the risk of the late-onset OHSS that pregnancy-derived hCG can cause. It does not remove every OHSS risk: symptoms can still appear in the days after retrieval and need the usual monitoring.
Why is single embryo transfer recommended so often?
Single embryo transfer (eSET) minimizes the likelihood of twin and higher-order multiple pregnancies, which carry significantly higher rates of preterm birth, pre-eclampsia, and neonatal complications.
Sources
- Practice Committee of the American Society for Reproductive Medicine. “Prevention of moderate and severe ovarian hyperstimulation syndrome: a guideline (2023).” Fertility and Sterility, 2024; 121(2): 230-245 (erratum: 2024; 123(4): 741). ASRM Guideline
- Practice Committee of the American Society for Reproductive Medicine. “Fertility drugs and cancer: a guideline (2024).” Fertility and Sterility, 2024; 122(3): 406-420. ASRM 2024
- The ESHRE Guideline Group on Ovarian Stimulation, Ata B, Bosch E, Broer S, et al. “ESHRE guideline: ovarian stimulation for IVF/ICSI: an update in 2025.” Human Reproduction, 2026; 41(4): 498-514. PMC13061131
- de Boer EJ, den Tonkelaar I, Burger CW, van Leeuwen FE, et al. “Are cause of subfertility and in vitro fertilization treatment risk factors for an earlier start of menopause?” Menopause, 2005; 12(5): 578-588. PubMed
- Practice Committee of the American Society for Reproductive Medicine and the Society for Assisted Reproductive Technology. “Guidance on the limits to the number of embryos to transfer: a committee opinion.” Fertility and Sterility, 2021; 116(3): 651-654. ASRM Committee Opinion
- Levi-Setti PE, Cirillo F, Scolaro V, et al. “Appraisal of clinical complications after 23,827 oocyte retrievals in a large assisted reproductive technology program.” Fertility and Sterility, 2018; 109(6): 1038-1043.e1. PubMed
- El-Shawarby SA, Margara RA, Trew GH, Lavery SA. “A review of complications following transvaginal oocyte retrieval for in-vitro fertilization.” Human Fertility, 2004; 7(2): 127-133. PubMed
Add as a Preferred Source on Google
You can add draksoyivf.com as one of your preferred health information sources on Google.
The content has been created by Dr. Senai Aksoy and medically approved.